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IN PRACTICE

CLINICAL UPDATE

Tuberous sclerosis complex in the Western Cape,
South Africa: The clinical presentation features
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Tuberous sclerosis complex (TSC) is a genetic neurocutaneous condition, which affects multiple organ systems. This study aimed to
determine the presenting features of children with TSC in Cape Town, South Africa. A cross-sectional study was conducted at a TSC clinic,
and clinical features at presentation were prospectively collected. Thirty-nine children (23 boys; median age 10 (range 1 - 26) years; median
diagnosis age 16 (0 - 153) months) were recruited. Twenty-one (54%) children presented with focal seizures. Seven (18%) children had
epileptic spasms. Skin manifestations led to a diagnosis in 13 (33%) and neuroimaging in 22 (56%) children. Antenatal screening detected
cardiac rhabdomyomas in 3 children. One child had a positive family history. In the paediatric service, TSC diagnosis usually followed
neuroimaging, whereas at the neurology service skin manifestations indicated TSC. In conclusion, most children with TSC presented
as emergency cases with seizures. Health practitioner awareness of the common TSC clinical signs was lacking, with the diagnosis often
delayed.
S Afr Med J 2017;107(4):295-298. DOI:10.7196/SAMJ.2017.v107i4.12040

Tuberous sclerosis complex (TSC) is a genetically inherited condition
that manifests with benign non-invasive hamartomas in multiple
organ systems and is associated with varied clinical presentations.[1,2]
The prevalence of TSC worldwide is reported as 1 in 6 000 newborns.[1-4]
Equivalent data from Africa are lacking. In Africa, the burden of disease is
dominated by infectious aetiologies. People with non-communicable
disorders, especially of genetic origin, have access to scarce resources
and are managed as low-priority cases. This results in disparate outcomes, e.g. in well-resourced settings awareness of TSC is more likely
to lead to early diagnosis, whereas in Africa management is reactive,
and limited resources and poor awareness lead to delayed diagnosis
and intervention.
Red Cross War Memorial Children’s Hospital (RCWMCH), Cape
Town, South Africa (SA) is unique in that it provides a dedicated
TSC service in the paediatric neurology department. The service
was established >15 years ago and has, during this period, managed
45 affected children. Based on international prevalence figures, this
number is less than expected for the region and raises concerns that
only a proportion of affected children access the service. The referral
pattern and disease demographics of the service were examined to
identify remedial factors to improve diagnosis and service delivery.

Objective

The objective of this study was to document the phenotype of SA
children with TSC, identifying clinical features at presentation, which
could lead to improvements in diagnosis in our setting.

Methods

RCWMCH is a university teaching hospital located in the Western
Cape, SA. For children with TSC a dedicated multidisciplinary service operates in the paediatric neurology department, in line with
international management guidelines. Patients are referred to our
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hospital by local health practitioners, based on concerns that arise
from the complications of TSC. As such, the understanding of referral
patterns was considered important to develop interventions to promote earlier identification of affected children, which would facilitate
preventive rather than reactive interventions.
All children attending the service between October 2013 and
August 2016 were prospectively recruited.
Patient demographics were recorded and compared with international data (Table 1).[5-7] Age at presentation, referral sources and
reason for referral were also documented.
Ethical clearance to conduct the study was granted by the Faculty of
Health Sciences Research Ethics Committee, University of Cape Town
(ref. no. 020/2013). Written consent was obtained from caregivers.

Results

Over the 33-month period, consent was obtained for 39 children
(23 males, 16 females; median 10 (range 1 - 26) years), who fulfilled
the international diagnostic criteria for TSC, to be part of the study.
From the original cohort attending the service (n=45), 5 children
had been referred to adult services, and 1 child died because of
complications unrelated to his TSC diagnosis.
Sixteen children were of indigenous black African ancestry, 9 were
white, 13 of mixed ancestry and 1 was Arabic. Median age at diagnosis
was 16 (0 - 153) months (Table 1).
Twenty-one (54%) children were referred to the general neuro
logy service owing to focal seizures, where TSC was diagnosed.
Diagnosis was delayed in four children. Two were mislabelled on
neuroimaging, specifically with neurocysticercosis in one child and
congenital cytomegalovirus in another. TSC was diagnosed following identification of hypopigmented skin lesions in the former
child and after persistent hypertension and identification of renal
angiomyolipomas in the latter. A third child suffered recurrent
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Table 1. Demographics of children attending the TSC service from October 2013 to August 2016 compared with those of other
similar paediatric cohort studies[5-7]
Variable

Current study, N=39

Yates et al., N=114

Datta et al.[6]
(infants only), N=41

Male:female

23:16

62:63

24:17

[5]

Erol et al.,[7] N=20
10:10

Age at presentation (months), median

16

7

1.5

11

Subependymal giant cell astrocytomas,* n (%)

10 (26)

5 (4)

4 (10)

1 (5)

Epilepsy, n (%)

34 (87)

-

-

17 (85)

Focal epilepsy, n (%)

21 (54)

-

-

7 (35)

Epileptic spasms (3 focal epilepsy and
epileptic spasms), n (%)

7 (18)

-

-

7 (35)

Cortical tubers,* n (%)

31 (79)

93 (89)

35 (85)

16 (80)

Subependymal nodules,* n (%)

36 (92)

76 (73)

37 (90)

16 (80)

Intellectual disability, n (%)

23 (59)

75 (85)

-

5/8 (63)

Angiomyolipoma,* n (%)

17 (44)

13 (12)

6 (15)

1 (5)

Cardiac rhabdomyoma,* n (%)

8 (20)

51 (58)

35 (85)

-

Facial angiofibroma,* n (%)

19 (49)

24 (29)

24 (29)

8 (40)

>3 hypomelanotic macules,* n (%)

27 (69)

80 (65)

21 (51)

17 (85)

Shagreen patch,* n (%)

10 (28)

30 (24)

30 (73)

2 (10)

Ungual and periungual fibroma,* n (%)

1 (0.02)

3 (2)

-

-

*International diagnostic criteria.[2]

pancreatitis, and her skin lesions were initially thought to be due to
a fungal infection. She eventually underwent a brain magnetic resonance imaging (MRI) scan and the skin lesions were re-examined.
A fourth child was resident in a rural part of the country. His learning and behavioural problems were well known to his caregivers, but
he attended the health service only when he was 12 years and 9 months
of age, with poorly controlled seizures.
Seven (18%) children had epileptic spasms, 4 at presentation, and
3 with focal seizures later developed spasms. The median lag time
from onset of epileptic spasms to diagnosis and intervention was 3 (2
- 8) months. Skin manifestations led to referral in 13 (33%) children,
who were already being managed for seizures. Neuroimaging as part
of routine screening for seizures resulted in confirmation of TSC in a
further 22 (56%) children. Three children with cardiac rhabdomyomas were identified antenatally, and 1 child with a positive family history was also diagnosed antenatally.
Most children were referred to the general neurology service as emergency cases with prolonged convulsive seizures, and a smaller proportion
were referred from the medical outpatient service with brief seizures. The
hospital location of the child at the time of diagnosis was distributed as
follows: medical outpatients (n=9), paediatrics (n=9), neurology (n=15),
antenatal obstetric service (n=3), and 1 each for genetics, gastroenterology and dermatology services. The key marker that led to the diagnosis
of TSC was predominantly based on neuroimaging findings after routine
investigation for seizures in children managed in the medical outpatient
service, and after the identification of skin lesions for children managed in the neurology service. Comparison between these diagnostic
markers for medical outpatients compared with neurology outpatients
demonstrated a trend, but it was not statistically significant on Fisher’s
exact test (p=0.058).
Prior to 2007, the median value for the number of new children
with TSC who were referred to the service was 1 per year; from 2007,
this number increased to a median value of 3 per year.
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Discussion

This study illustrated that awareness of TSC in SA health services
is poor. TSC was suspected in only a few children, based on the
presence of skin lesions; their referral to the neurology service
was typically because of recurrent seizures. Most of the remaining
children presented after acute presentations with seizures, and the
diagnosis of TSC was made following admission for emergency
management. Children in our cohort presented later than those
reported in international studies (Table 1). As found in our study
and in large international studies, the presenting features of TSC
can be diverse – prior to their diagnosis a proportion of our children
were under direct management in the genetics, gastroenterology and
dermatology services.[4] The skin manifestations of 2 of the patients were
detected, but incorrectly interpreted. In settings where conditions
such as neurocysticercosis are prevalent, erroneous assumptive diag
noses based on neuroimaging findings may also occur, as illustrated
in this study.
Hypomelanocytic macules may be present at birth, and other skin
manifestations such as facial angiofibroma and shagreen patches
appear later during the first decade of life.[2] In this study, even though
hypomelanocytic macules were found in 69% of patients, the diagnosis of TSC was suspected at referral in only 33% of cases (Table 1).
The 2012 international guidelines on the diagnosis and management of TSC emphasise the importance of early diagnosis to improve
the outcome of affected children.[1] Epileptic spasms are common
during the first year of life in children with TSC. These children may
also have focal seizures, which may occur either before or after onset
of epileptic spasms. Corticosteroids are the recommended treatment
for infants with epileptic spasms who do not have TSC, while vigabatrin is the most effective intervention in infants with TSC.[8] Delayed
recognition of TSC can lead to suboptimal intervention for epileptic
encephalopathy. The guidelines recommend presymptomatic electroencephalography (EEG) in the age group at risk of epileptic spasms.[2,5]
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While this is a viable intervention at our centre, patients in this study
typically had already evolved seizures as a presenting complaint.
Furthermore, EEG is a scarce resource in low- and low-middleincome countries in Africa and many centres struggle to access such
testing. Epileptic spasms were identified in 18% of the children in our
study, which is similar to the percentage in other studies.[9]
The guidelines have similar recommendations for renal monitoring
to screen for angiomyolipomas. Even though this is also a rational
recommendation, it is unlikely to be fullfilled in many parts of subSaharan Africa.[1,2,10] In our group, 3 patients presented with cardiac
rhabdomyomas, and 5 had lesions identified after TSC was diagnosed.
It is possible that these additional cases reflected limited antenatal
assessment, and further highlights the difficulties of early detection
in our setting.[11] The challenges illustrated here highlight the need
for these children to be managed in a tertiary setting, where adequate
multidisciplinary care can be provided, and the drain on already
stretched secondary and primary healthcare services can be avoided.
The study by Yates et al.[5] reported similar presentation triggers
and phenotypic features as in our cohort, but in a population in the
UK. One hundred and fourteen children in this study met the criteria
for TSC and 17% were diagnosed in the antenatal period, compared
with 8% of our patients.[5] Thirty children (24%) in the UK study
presented before the onset of seizures, which affected 77 (62%) of the
group.[5] In our population, the diagnosis of TSC before neuroimaging
for new onset of seizures occurred less often than in the Yates et al.[5]
study, but the proportion of children presenting with seizures was
comparable (62% in the UK study v. 56% in the current study). The
UK study also found an increasing number of children presenting
prenatally or in early infancy, which reflected both the increased
awareness of TSC and appropriate resources available to identify
affected patients.[5]
The international TSC guidelines also recommend early neurodevelopmental screening to optimise performance outcomes. This
would permit appropriate school placement and learning support
to be initiated. There are challenges to such implementation in our
setting, especially where there are additional compounding factors
of poor socioeconomic structure, and layering effects from other
comorbidities, such as HIV and tuberculosis. In most parts of Africa,
there is limited access to developmental intervention, with few skilled
health practitioners and long waiting lists.
Subependymal giant cell astrocytomas (SEGAs) are some of the
more serious complications of TSC. International guidelines recommend regular monitoring and awareness of early symptoms and signs
to facilitate early intervention.[1] The current study found a higher
proportion of children with SEGAs compared with the UK, USA and
Turkey.[5-7] This may reflect disease behaviour, whereby only the most
symptomatic patients access healthcare services in our setting. In SA,
there is no effective structure for routine screening of asymptomatic
children for TSC.
Genetic testing is useful to confirm the diagnosis of TSC and
for family counselling.[5] Currently, genetic testing is not routinely
available in SA and fulfilment of clinical criteria is used to confirm
a diagnosis of TSC. However, the service does have access to genetic
counsellors, who provide families with support. A previous study[12]
showed that caregivers, who despite regular attendance at the clinic,
often failed to understand the condition and benefited when provided with written information, preferably in their home language
or language of choice. This study highlights that there is a great need
to raise awareness of TSC in our setting. Based on service referral
patterns, opportunities to achieve this could be by promoting TSC
teaching in undergraduate curricula, in community projects, and by
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raising awareness in primary healthcare clinics. Informative posters
could be placed in strategic settings, such as primary healthcare clinics and community centres. In SA, a national TSC non-governmental
organization is yet to be established, but there are other routes of
support, such as Rare Diseases SA (http://rarediseases.co.za/) and
Epilepsy SA (http://epilepsy.org.za).
Many of the patients were incidentally diagnosed by neuroimaging
performed as part of evaluation of their seizure disorder. In our setting, neuroimaging is not usually performed unless there is concern
of focal pathology. Further, in our experience seizures are often
erroneously assumed to be generalised, also reducing the likelihood
of performing neuroimaging. This highlights the need for extracting
a good clinical seizure semiology and performing a careful clinical
examination, as the majority of affected children have skin manifestations. Since 2007, the RCWMCH TSC service has actively promoted
awareness of common clinical markers for TSC within the hospital
structure – a tertiary care facility. The median annual referral rate has
tripled. While this is a positive trend, heightened awareness needs
to be facilitated at primary and secondary facilities as the next stage.
Based on the apparent scarcity of recognition and limited awareness
of TSC in SA, which, compared with other parts of Africa, has greater
access to resources, it is likely that the challenges of diagnosing TSC are
even more pronounced in the rest of the continent. The late diagnosis
of TSC in adulthood is associated with greater complications.[13]

Conclusion

In this study, most children with TSC presented as emergency
cases with seizures. Awareness of the common clinical markers at
presentation is lacking. We aimed to gain insight into the referral
patterns of children with TSC to a specialised service to identify
ways to improve early identification of and intervention with regard
to the condition. The next stage will be an intervention study to
observe if the recruitment can be improved by raising awareness in
the key locations where these children present, inclusive of primary
healthcare clinics, community bases, and school healthcare clinics.
TSC prevalence is estimated internationally at 1 in 6 000 newborns,
and based on our population of 2.14 million children <19 years of age
in the Western Cape, some 357 children in this region may have TSC.[14]
The majority of affected children in our area and potentially sub-Saharan
Africa are probably not diagnosed. This highlights the need to raise
awareness of such common clinical markers to promote early referral to
specialist centres to reduce complications.
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